(Q36349741)

13 August 2017

title

Drug-induced glomerulopathies (English)

1 reference

13 August 2017

4

Isabelle Brocheriou

0 references

Vincent Launay-Vacher

2

object named as

Vincent Launay-Vacher

1 reference

13 August 2017

Hassan Izzedine

1

1 reference

13 August 2017

Edward Bourry

3

1 reference

13 August 2017

Isabelle Brocheriou

4

1 reference

13 August 2017

Svetlana Karie

5

1 reference

13 August 2017

Gilbert Deray

6

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Drug Safety

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

95-106

1 reference

The nephrotoxic potential of drugs and chemicals. Pharmacological basis and clinical relevance

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Proteinuria in gold-treated rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Recognition and management of children with increased lead absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Bucillamine induces membranous glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Membranous nephropathy caused by mercury-containing skin lightening cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Drug-associated glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nephrotic syndrome and immune complex glomerulonephritis associated with chlorpropamide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Renal syndromes associated with nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Drug-induced acute interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Focal segmental glomerulosclerosis in patients receiving lithium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Forty years of lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Minimal-change disease and the nephrotic syndrome associated with lithium therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nephrotic syndrome and renal insufficiency associated with lithium therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Overview of fluoroquinolone safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nephrotic Syndrome after Norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Norfloxacin-induced nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nephrotic syndrome and interstitial nephritis associated with celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Pathologic classification of focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Focal segmental glomerulosclerosis and lithium treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Minocycline induced arthritis associated with fever, livedo reticularis, and pANCA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Drug therapy. Drug allergy (second of three parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Rifampin-induced nephrotic syndrome and acute interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Rapidly progressive glomerulonephritis during antituberculous therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Isoniazid-induced crescentic glomerulonephritis in a child with a positive tuberculin skin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

ANCA-positive crescentic glomerulonephritis associated with minocycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Trimethadione (Tridione)-induced nephrotic syndrome. A report of a case with unique ultrastructural renal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Renal manifestations of drug-induced systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Naproxen-induced nephropathy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Drugs recently associated with lupus syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Foscarnet nephrotoxicity: mechanism, incidence and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Foscarnet and crystals in glomerular capillary lumens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.1.95

21 January 2018

Identifiers

DOI

10.1517/14740338.5.1.95

1 reference

13 August 2017

1 reference